Novabay Pharmaceutic Sees Large Growth in Short Interest (NBY)
Novabay Pharmaceutic (NYSE:NBY) was the recipient of a significant growth in short interest in the month of August. As of August 15th, there was short interest totalling 602,915 shares, a growth of 13.6% from the July 31st total of 530,576 shares, Analyst RN reports. Approximately 1.6% of the company’s shares are sold short. Based on an average daily trading volume, of 186,492 shares, the short-interest ratio is presently 3.2 days.
Novabay Pharmaceutic (NYSE:NBY) opened at 0.77 on Wednesday. Novabay Pharmaceutic has a one year low of $0.69 and a one year high of $2.03. The stock’s 50-day moving average is $0.95 and its 200-day moving average is $1.02. The company’s market cap is $39.1 million.
Novabay Pharmaceutic (NYSE:NBY) last issued its quarterly earnings data on Thursday, July 31st. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.03. Analysts expect that Novabay Pharmaceutic will post $-0.30 EPS for the current fiscal year.
NovaBay Pharmaceuticals, Inc (NYSE:NBY) is a clinical-stage pharmaceutical company, which is engaged in the discovery and development of synthetic anti-infective product candidates to treat and prevent a range of infections, without developing resistance, in hospital and non-hospital environments.
Receive News & Ratings for Novabay Pharmaceutic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novabay Pharmaceutic and related companies with Analyst Ratings Network's FREE daily email newsletter.